Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cortivazol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 18/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortivazol SCHEMBL21340660 | 0.95 | KDM4E (0.82) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL4875 | 0.95 | KDM4E (0.82) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL6820239 | 0.94 | KDM4E (0.81) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL10455984 | 0.94 | KDM4E (0.81) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL22946293 | 0.89 | KDM4E (0.71) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL11946698 | 0.89 | KDM4E (0.71) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL21340662 | 0.88 | KDM4E (0.70) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL21231563 | 0.87 | KDM4E (0.69) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL29610995 | 0.86 | KDM4E (0.85) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL22946295 | 0.86 | KDM4E (0.67) | KDM4EMEN1KMT2ANPSR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104203901-A | Compositions and methods for the treatment of inflammation | RESOLVYX PHARMACEUTICALS INC | 2014-12-10 | — | — | CN | disclosed |
| CN-103140215-A | Pharmaceutical composition with enhanced solubility characteristics | ALCON RES LTD | 2013-06-05 | — | — | CN | disclosed |
| CN-101687042-A | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye | ALCON LAB INC | 2010-03-31 | — | — | CN | disclosed |
| EP-1962803-A1 | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE | Alcon, Inc. (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007076358-A1 | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE | ALCON, INC. (CH) | 2007-07-05 | — | — | WO | disclosed |